Skip to main content

Table 1 Study characteristics, methodological design choices, surveying techniques, and quality of the included disability weights measurement studies

From: A systematic literature review of disability weights measurement studies: evolution of methodological choices

Author

Year

Region or country included

Single- or Multi-cause study?

Panel of judges

Number of the panel members

Number of health states valued

Description of health states

Time Presentation

Valuation methods for health states

Surveying technique/tool

Number of tasks per panel member

CREATE score (%)

Asadi et al. [37]

2016

Iran

Single (Poisonings)

ME

10

50

DS

Period Profile

Interpolation

Questionnaire

NA

93

Bae et al. [49]

2019

Korea

Single (Osteoporosis; osteoporotic fractures)

ME

33

6

NA

Period Profile

PTO

Face-to-face interview

6

87

Bakhshandeh et al. [45]

2009

Iran

Single (Cardiovascular diseases)

HP, PT, PX, PP

80

25

DS

NA

VAS (ranking)

Face-to-face interview

25

80

Baltussen et al. [50]

2002

Burkina Faso

Multiple

HP, PP

56

9

DS (scenario analyses)

Period Profile

Adapted VAS/ Interpolation

Group discussion & Questionnaire

9

93

Basiri et al. [38]

2008

Iran

Single (Urological disease)

ME

10

76

NA

Period Profile

Interpolation

Questionnaire

10

87

Brennan & Spencer [40]

2004

Australia

Single (Oral disease)

Model

NA

18

EQ-5D

Period Profile

EQ-5D: NA

NA

NA

100

Brennan et al. [39]

2007

Australia

Single (Peridontal disease)

Model

NA

6

EQ-5D

Period Profile

EQ-5D: NA

NA

NA

100

Cho et al. [46]

2014

Korea

Single (Multiple sclerosis)

ME

15

5

DS

Period Profile

PTO

Modified Delphi method

NA

87

Choi et al. [47]

2013

Korea

Single (Cancer)

ME

32

24

NA

Period Profile

VAS & PTO

NA

24

87

Gabbe et al. [33]

2016

Netherlands, United States, New Zealand, Australia, United Kingdom

Single (Injury)

Model

NA

40

EQ-5D

Period Profile

EQ-5D: NA

NA

NA

100

Haagsma et al. [34]

2008

Netherlands

Single (Injury)

PP

143

44

DS & EQ-5D

Annual profile

VAS & TTO

Panel meeting & Questionnaire

32

100

Haagsma et al. [51]

2008

Netherlands

Multiple

PP

107

39

DS & EQ-5D

Annual profile

VAS & PTO

Panel meeting & Questionnaire

27

100

Haagsma et al. [35]

2009

Netherlands

Single (Injury)

Model

NA

7

EQ-5D

Period Profile

EQ-5D: NA

NA

NA

100

Haagsma et al. [14]

2015

Hungary, Italy, Netherlands, Sweden

Multiple

PP

30,660

255

DS

Period Profile

PC & PHE

Web-based survey

18

100

Hong & Saver [44]

2009

United States, Southeast Asia

Single (Stroke)

ME

9

5

NA

NA

PTO

Panel meeting & Questionnaire

5

80

Havelaar et al. [41]

2000

Netherlands

Single Infectious disease

ME

35

NA

NA

Period Profile

Interpolation

Panel meeting

NA

93

Jelsma et al. [52]

2000

Zimbabwe

Multiple

ME, PP

68

22

NA

Period Profile

VAS & PR

Focus group discussion

NA

80

Kim et al. [53]

2020

Korea

Multiple

ME

806

313

DS

Period Profile

PR

Web-based survey

20

93

Kruijshaar et al. [54]

2005

Netherlands

Multiple

ME

49

18

DS & EQ-5D

Period Profile

Interpolation

Questionnaire

18

100

Kwong et al. [55]

2010

Canada

Multiple

Model

NA

NA

CLAMES

Period Profile

CLAMES: NA

NA

NA

100

Lai et al. [56]

2009

Estonia

Multiple

ME

25

283

DS

Period Profile

VAS & PTO

Panel meeting

NA

93

Lyons et al. [36]

2011

United Kingdom

Single (Injury)

Model

NA

13

EQ-5D

Period Profile

EQ-5D: NA

NA

NA

93

Mathers et al. [57]

2000

Australia

Multiple

Model

NA

NA

EQ-6D & DDW

Period Profile

EQ-6D: NA

NA

NA

100

Murray et al. [8]

1996

Global

Multiple

ME

10

483

DS

Period Profile

VAS & PTO

NA

NA

87

Nanjan Chandran et al. [17]

2021

Global

Single (Lepropsy)

PP

667

3

SF-36 HRQoL data

NA

SF-36 HRQoL data: NA (meta-analysis)

NA

NA

100

Neethling et al. [16]

2016

South Africa

Multiple

PP

677

51

DS (no label)

Period Profile

PC & TTO

Household face-to-face interview

15

100

Nontarak et al. [58]

2020

Thailand

Multiple

PT

450

9

DS & EQ-5D

Period Profile

VAS & EQ-5D & TTO

Face-to-face interview

NA

87

Nontarak et al. [42]

2021

Thailand

Single (Alcohol use disorders)

PT, PP

300

3

DS & EQ-5D

Period Profile

VAS & EQ-5D & TTO

Face-to-face interview

NA

93

Nomura et al. [13]

2021

Japan

Multiple

PP

37,318

231

DS (no label)

Period Profile

PC & PHE

Web-based survey

18

100

Ock et al. [59]

2016

Korea

Multiple

HP

496

228

DS

Period Profile

PC & PTO

Web-based survey

60

93

Ock et al. [15]

2016

Korea

Multiple

PP

5916

256

DS

Period Profile

PC & VAS & SG & PHE

Household survey & Web-based survey

22

93

Ock et al. [60]

2019

Korea

Multiple

HP

605

289

DS (no label)

Period Profile

PR

Web-based survey

20

93

Park & Jung [61]

2017

Korea

Multiple

Model

NA

243

EQ-5D

NA

EQ-5D: NA

NA

 

100

Piao et al. [62]

2021

Japan

Multiple

HP

286

17

DS

Period Profile

PC & PHE

Questionnaire

NA

87

Poenaru et al. [18]

2017

Kenya, Canada

Single (Paediatric conditions)

HP

154

15

DS & EQ-5D

NA

PR & VAS & PC & TTO

Focus groups

NA

87

Rehm & Frick [63]

2013

United States

Multiple

ME

68

12

DS + CLAMES

NA

PC & PR & PTO

NA

NA

87

Salomon et al. [12]

2012

Global

Multiple

PP

30,230

220

DS (no label)

Period Profile

PC & PHE

Household survey; Web-based survey

18

100

Salomon et al. [20]

2015

Global

Multiple

PP

30,230 & 30,660

235

DS (no label)

Period Profile

PC

Web-based survey (GBD 2010; European surveys; Household surveys; USA surveys)

18

100

Sanderson et al. [43]

2001

Australia

Sinlge (Mental disorders)

ME

20

19

DS

NA

PTO & Rating scale & PR

Panel meeting

19

87

Schwarzinger et al. [64]

2003

Europe

Multiple

ME, nHP

232

15

DS & EQ-5D

Period Profile

VAS & PTO & TTO

Panel meeting

15

93

Steckling et al. [19]

2017

Global

Multiple

ME

18

105

DS & EQ-5D

Period Profile

VAS & PC/ Interpolation

Web-based survey

NA

87

Stouthard et al. [65]

1997

Netherlands

Multiple

ME

38

175

DS & EQ-5D

Period Profile & Annual Profile

VAS & PTO

Panel meeting & Questionnaire

47

93

Ustün et al. [66]

1999

Global

Multiple

HP, PT, PX, PM

241

17

DS

Period Profile

PR

Interview

17

93

Van Spijker et al. [67]

2011

Netherlands

Multiple

ME

16

12

DS & EQ-5D

Period Profile

VAS

Questionnaire

12

100

Yoon et al. [48]

2000

Korea

Single (Cancer)

ME

19

12

NA

NA

PTO & Interpolation

Delphi method

NA

80

Yoon et al. [68]

2007

Korea

Multiple

ME

30

123

NA

Period Profile

PTO & Interpolation

Panel meeting

53

93

  1. NA Not Available, DDW Dutch Disability Weight
  2. Panel of judges
  3. ME Medical experts, HP Health professionals, nHP Non-health professionals, PT Patients or people with disabilities, PX Patient proxies, PM Policy-makers, PP Population
  4. Description of health states
  5. DS Disease-specific health state description, EQ-5D European Quality of Life instrument that consists of five dimensions/attributes (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), EQ-6D EQ-5D appended with a cognitive dimension/attribute, CLAMES Classification and Measurement System of Functional Health, SF-36 HRQoL Short form health-related quality of life survey
  6. Valuation methods for health states
  7. VAS Visual analog scale, TTO Time trade-off PTO Person trade-off, PC Paired comparison, PHE Population health equivalence, PR Preference ranking, SG Standard gamble
  8. CREATE
  9. CREATE: Checklist for Reporting Valuation Studies instrument